Excluding COVID-Related Sales, Bio-Rad Estimates FY23 Currency-Neutral Revenue Growth To Be About 4.5% (Prior 8.5%)
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories, Inc. (BIO) has revised its FY23 currency-neutral revenue growth estimate to about 4.5%, down from the previous estimate of 8.5%. This revision excludes COVID-related sales.
August 04, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bio-Rad's revised FY23 revenue growth estimate could potentially impact its stock price negatively in the short term.
Bio-Rad's downward revision of its FY23 revenue growth estimate, excluding COVID-related sales, could be perceived negatively by investors. This could potentially lead to a decrease in demand for the company's stock, thereby negatively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100